Ticker

-- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data -- -- Aligned with U.S. Food and Drug Administration on Registrational Path for Luvesilocin in Postpartum Depression (PPD); On Track to Initiate Phase 3 Trial in 2026 --  MORRISTOWN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the…

MORRISTOWN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced its participation in the following upcoming conferences:

-- Aligned with U.S. Food and Drug Administration (FDA) on Registrational Path for RE104 in Postpartum Depression (PPD); On Track to Initiate Phase 3 Trial in 2026 --  -- Enrolling Phase 2 REKINDLE Trial of RE104 in Adjustment Disorder (AjD); Initial Data Expected in 1Q 2027 -- -- On Track to Initiate Phase 2 RECLAIM Trial in Generalized Anxiety Disorder (GAD) in 1Q 2026 -- MORRISTOWN, N.J., Jan. 12, 2026 (GLOBE…